The HDAC inhibitor valproate induces a bivalent status of the CD20 promoter in CLL patients suggesting distinct epigenetic regulation of CD20 expression in CLL in vivo.
about
The HDAC inhibitor valproate induces a bivalent status of the CD20 promoter in CLL patients suggesting distinct epigenetic regulation of CD20 expression in CLL in vivo.
description
2017 nî lūn-bûn
@nan
2017 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2017 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
name
The HDAC inhibitor valproate i ...... D20 expression in CLL in vivo.
@ast
The HDAC inhibitor valproate i ...... D20 expression in CLL in vivo.
@en
type
label
The HDAC inhibitor valproate i ...... D20 expression in CLL in vivo.
@ast
The HDAC inhibitor valproate i ...... D20 expression in CLL in vivo.
@en
prefLabel
The HDAC inhibitor valproate i ...... D20 expression in CLL in vivo.
@ast
The HDAC inhibitor valproate i ...... D20 expression in CLL in vivo.
@en
P2093
P2860
P356
P1433
P1476
The HDAC inhibitor valproate i ...... D20 expression in CLL in vivo.
@en
P2093
Annarita Scialdone
Jesper Kofoed Damm
Kristina Drott
Muhammad Sharif Hasni
Urban Gullberg
P2860
P304
37409-37422
P356
10.18632/ONCOTARGET.16964
P407
P577
2017-04-08T00:00:00Z